Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01191268 · ClinicalTrials.gov registry record · Phase 3
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 884
- Enrollment target
NCT01191268 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 884 participants.
The verdict
NCT01191268, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 884 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of LY2189265 in comparison to Insulin Glargine, both in combination with Insulin Lispro (plus or minus Metformin), in participants with Type 2 Diabetes treated with 1 or 2 injections of insulin.
Interventions
- DRUG Insulin Glargine
- DRUG Insulin Lispro
- DRUG LY2189265
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 884 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01191268
The ClinicalTrials.gov registry entry for NCT01191268 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 884 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Insulin Glargine is the first listed.
NCT01191268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01191268 about?
NCT01191268 is a clinical study titled "A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)". The purpose of this study is to assess the efficacy and safety of LY2189265 in comparison to Insulin Glargine, both in combination with Insulin Lispro (plus or minus Metformin), in participants with Type 2 Diabetes treated with 1 or 2 injections of insulin.
What is the current status of trial NCT01191268?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 884 participants. The study started on 2010-11. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01191268?
The interventions under investigation include: Insulin Glargine (DRUG), Insulin Lispro (DRUG), LY2189265 (DRUG).
Who is sponsoring clinical trial NCT01191268?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.